NASDAQ:TCRR

TCR2 Therapeutics Stock Forecast, Price & News

$30.72

-0.90 (-2.85 %)

(As of 01/20/2021 12:00 AM ET)

Add

Compare

Today's Range

$30.02

Now: $30.72▼

$32.70

50-Day Range

$27.06

MA: $30.92▼

$34.07

52-Week Range

$5.84

Now: $30.72▼

$35.86

Volume1.96 million shs

Average Volume529,904 shs

Market Capitalization$1.03 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.13

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include TC-210, mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which initiated in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies. Its product candidates in pipeline focuses on adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma areas. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Overall MarketRank^™

1.53 out of 5 stars

Medical Sector

642nd out of 1,928 stocks

Biological Products, Except Diagnostic Industry

83rd out of 177 stocks

3.5 Analyst's Opinion

Consensus Rating
TCR2 Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $39.29, TCR2 Therapeutics has a forecasted upside of 27.9% from its current price of $30.72.
Amount of Analyst Coverage
TCR2 Therapeutics has only been the subject of 4 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
TCR2 Therapeutics has received 98 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
TCR2 Therapeutics has received 97 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
TCR2 Therapeutics has received 50.26% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about TCR2 Therapeutics and other stocks. Vote “Outperform” if you believe TCRR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TCRR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
TCR2 Therapeutics does not currently pay a dividend.
Dividend Growth
TCR2 Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TCR2 Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $491,980.00 in company stock.
Percentage Held by Insiders
Only 27.99% of the stock of TCR2 Therapeutics is held by insiders.
Percentage Held by Institutions
82.05% of the stock of TCR2 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for TCR2 Therapeutics are expected to decrease in the coming year, from ($2.44) to ($2.49) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of TCR2 Therapeutics is -12.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TCR2 Therapeutics is -12.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
TCR2 Therapeutics has a P/B Ratio of 4.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:TCRR

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.tcr2.com

Phone617-949-5200

Employees109

Debt

Debt-to-Equity RatioN/A

Current Ratio32.38

Quick Ratio32.38

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$6.68 per share

Price / Book4.60

Profitability

EPS (Most Recent Fiscal Year)($4.62)

Net Income$-47,600,000.00

Net MarginsN/A

Return on Equity-35.51%

Return on Assets-34.02%

Miscellaneous

Outstanding Shares33,422,000

Market Cap$1.03 billion

Next Earnings Date3/29/2021 (Estimated)

OptionableNot Optionable

$30.72

-0.90 (-2.85 %)

(As of 01/20/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive TCRR News and Ratings via Email

Sign-up to receive the latest news and ratings for TCRR and its competitors with MarketBeat's FREE daily newsletter.

TCR2 Therapeutics (NASDAQ:TCRR) Frequently Asked Questions

How has TCR2 Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

TCR2 Therapeutics' stock was trading at $8.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TCRR stock has increased by 258.0% and is now trading at $30.72.
View which stocks have been most impacted by COVID-19.

Is TCR2 Therapeutics a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TCR2 Therapeutics stock.
View analyst ratings for TCR2 Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than TCR2 Therapeutics?

Wall Street analysts have given TCR2 Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but TCR2 Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as TCR2 Therapeutics' CEO?

1,428 employees have rated TCR2 Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among TCR2 Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is TCR2 Therapeutics' next earnings date?

TCR2 Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for TCR2 Therapeutics.

How were TCR2 Therapeutics' earnings last quarter?

TCR2 Therapeutics Inc. (NASDAQ:TCRR) announced its quarterly earnings data on Thursday, November, 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.52) by $0.04.
View TCR2 Therapeutics' earnings history.

What price target have analysts set for TCRR?

7 brokerages have issued 12 month price objectives for TCR2 Therapeutics' stock. Their forecasts range from $25.00 to $65.00. On average, they expect TCR2 Therapeutics' share price to reach $39.29 in the next year. This suggests a possible upside of 27.9% from the stock's current price.
View analysts' price targets for TCR2 Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of TCR2 Therapeutics' key competitors?

Some companies that are related to TCR2 Therapeutics include SpringWorks Therapeutics (SWTX), Ablynx (ABLYF), Kymera Therapeutics (KYMR), bluebird bio (BLUE), NanoString Technologies (NSTG), Revolution Medicines (RVMD), AlloVir (ALVR), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Bavarian Nordic A/S (BVNRY), Replimune Group (REPL), NantKwest (NK), Vericel (VCEL), Scholar Rock (SRRK) and REGENXBIO (RGNX).
View all of TCRR's competitors.

What other stocks do shareholders of TCR2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).

Who are TCR2 Therapeutics' key executives?

TCR2 Therapeutics' management team includes the following people:

Dr. Garry E. Menzel M.B.A., Ph.D., Pres, CEO & Director (Age 56, Pay $775.38k)
Mr. Mayur Amrat Somaiya, Chief Financial Officer (Age 47, Pay $523.91k)
Dr. Alfonso QuintÃ¡s Cardama M.D., Chief Medical Officer (Age 49, Pay $595.46k)
Mr. Robert Hofmeister Ph.D., Chief Scientific Officer (Age 52)
Carl Mauch, Director of Investor Relations & Corp. Communications
Ms. Margaret Siegel, Head of Legal & Corp. Sec.
Dr. Angela Justice Ph.D., Chief People Officer (Age 48)
Mr. Gregg McConnell M.B.A., Head of Bus. Devel.
Mr. Stephen Turkowiak M.B.A., VP of Fin. & Treasurer

When did TCR2 Therapeutics IPO?

(TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at a price of $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is TCR2 Therapeutics' stock symbol?

TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

Who are TCR2 Therapeutics' major shareholders?

TCR2 Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Pacer Advisors Inc. (0.00%). Company insiders that own TCR2 Therapeutics stock include Mayur Ian Somaiya, Morana Jovan-Embiricos, Neil W Gibson, Robert Hofmeister and Upnorth Investment Ltd.
View institutional ownership trends for TCR2 Therapeutics.

Which major investors are buying TCR2 Therapeutics stock?

TCRR stock was bought by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have bought TCR2 Therapeutics stock in the last two years include Morana Jovan-Embiricos, and Upnorth Investment Ltd.
View insider buying and selling activity for TCR2 Therapeutics or or view top insider-buying stocks.

How do I buy shares of TCR2 Therapeutics?

Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TCR2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $30.72.

How big of a company is TCR2 Therapeutics?

TCR2 Therapeutics has a market capitalization of $1.03 billion. The company earns $-47,600,000.00 in net income (profit) each year or ($4.62) on an earnings per share basis. TCR2 Therapeutics employs 109 workers across the globe.

What is TCR2 Therapeutics' official website?

The official website for TCR2 Therapeutics is www.tcr2.com.

How can I contact TCR2 Therapeutics?

TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-949-5200 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here